Shandong Henglu develops and manufactures products grounded in core patented technologies including human milk oligosaccharides (HMOs), marine biological peptides, and high‑purity Rhodiola. Founded in March 2018, the company integrates R&D, production and sales. It has translated its research into products for special medical formula foods, biopharmaceuticals, and medical cosmetics under a full‑process safe, green production model. Financially, the company has received outside capital from Huayao Capital: a ¥30M investment in 2020 and a subsequent ¥24M follow‑on commitment. The latest funding is designated to advance HMO and high‑purity Rhodiola projects and to support team building. Company leadership and its investors cite the team’s international‑level innovation and the strong market opportunity for HMOs as drivers for continued support.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2021